A Big Test Is Looming for Pfizer, Moderna, and Novavax
Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and Novavax (NASDAQ: NVAX) were all popular stocks to own when demand for COVID vaccines was strong. But these companies are all preparing for what's likely to be a soft year in 2023 and a big decline in revenue from the previous year. demand for vaccines is still there, but whether it's enough for these companies to hit their forecasts this year is questionable.
Here's why the latter half of the year could make or break these stocks.
Fall season is also flu season, and it's a time when people are accustomed to receiving their annual shots. This year it will also serve as the first big test of demand for COVID shots. COVID vaccine makers Pfizer, Moderna, and Novavax have been working on updated vaccines that target new variants. One of the most concerning has been XBB.1.5, which has led to a worrisome increase in COVID cases in China.
Source Fool.com
Pfizer Inc. Aktie
Pfizer Inc. sticht hervor mit 28 Buy- und nur 4 Sell-Einschätzungen.
Das Kursziel von 41 € für Pfizer Inc. bedeutet eine deutliche Steigerung von über 20% gegenüber dem aktuellen Kurs von 27.44 €.
